

Review

Marine Bacterial Sialyltransferases

Takeshi Yamamoto

Glycotechnology Business Unit, Japan Tobacco Inc., 700 Higashibara, Iwata, Shizuoka 438-0802, Japan; E-Mail: takeshi.yamamoto@jt.com; Tel.: +81-538-32-7389; Fax: +81-538-32-6046

Received: 20 September 2010; in revised form: 25 October 2010 / Accepted: 2 November 2010 /

Published: 5 November 2010

Abstract: Sialyltransferases transfer *N*-acetylneuraminic acid (Neu5Ac) from the common donor substrate of these enzymes, cytidine 5'-monophospho-*N*-acetylneuraminic acid (CMP-Neu5Ac), to acceptor substrates. The enzymatic reaction products including sialyl-glycoproteins, sialyl-glycolipids and sialyl-oligosaccharides are important molecules in various biological and physiological processes, such as cell-cell recognition, cancer metastasis, and virus infection. Thus, sialyltransferases are thought to be important enzymes in the field of glycobiology. To date, many sialyltransferases and the genes encoding them have been obtained from various sources including mammalian, bacterial and viral sources. During the course of our research, we have detected over 20 bacteria that produce sialyltransferases. Many of the bacteria we isolated from marine environments are classified in the genus *Photobacterium* or the closely related genus *Vibrio*. The paper reviews the sialyltransferases obtained mainly from marine bacteria.

Keywords: marine bacteria; *Photobacterium*; sialyltransferase; sialic acid

1. Introduction

Sialic acids are important components of carbohydrate chains and are usually found on the terminal position of the carbohydrate moiety of glycoconjugates, including glycoproteins and glycolipids [1,2]. Many studies have shown that the sialyloligosaccharides of glycoconjugates play significant roles in many biological processes, such as inflammatory and immunological responses, cell-cell recognition, cancer metastasis and viral infection [3–7]. The transferring of sialic acids to carbohydrate chains is performed by specific sialyltransferases in the cell [2,8]. Therefore, the sialyltransferases are considered to be key enzymes in the biosynthesis of sialylated glycoconjugates. Detailed investigations of the biological functions of sialylated-glycoconjugates require an abundant supply of the target compounds. Chemical and enzymatic glycosylation have been the two major routes for the preparation

of sialylated-glycoconjugates. Although chemical glycosylation has the advantage of high flexibility and wide applicability, the reaction processes are complicated as the chemical reactions often require multiple protection and de-protection steps [9–11]. On the other hand, enzymatic glycosylation using glycosyltransferases is a single-step process with high positional and anomer selectivity and high reaction yield. For example, in sialylation, the transfer of Neu5Ac by sialyltransferases from CMP-Neu5Ac to the appropriate substrate can be readily achieved under mild reaction conditions [12]. Generally, bacterial enzymes are more stable and productive in *Escherichia coli* protein expression systems than the mammalian-derived enzymes, and mammalian enzymes have stricter acceptor specificity. Therefore, we have screened many marine bacteria for novel sialyltransferase activity to enzymatically produce sialylated glycoconjugates and sialyloligosaccharides in large amounts. During the course of our research, we have identified over 20 bacteria that produce sialyltransferases, many of which are classified in the genus *Photobacterium* or the closely related genus *Vibrio* [13]. Furthermore, we have also revealed that the bacteria-derived sialyltransferases show broader acceptor substrate specificity than the mammalian enzymes [13]. These advantages highlight the capacity of bacterial enzymes to serve as efficient tools for the *in vitro* enzymatic modification or/and synthesis of sialylated-glycoconjugates and sialyloligosaccharides [13].


2. Sialic Acid

2.1. Structure and distribution

Sialic acids (Sias) are a family of monosaccharides comprising over 50 naturally occurring derivatives of neuraminic acid, 5-amino-3,5-dideoxy-D-glycero-D-galacto-2-nonulosonic acid (Neu) [1,2]. Structurally, the Sia derivatives of Neu carry a variety of substitutions at the amino and/or hydroxyl groups. The amino acid group is often acetylated, glycolylated, or replaced by a hydroxyl group. The hydroxyl groups can be acetylated at O4, O7, O8, or O9, singly or in combination [2], and can also be modified by acetate, lactate, phosphate or sulfate esters.

The three major members of the Sia group are *N*-acetylneuraminic acid (Neu5Ac), *N*-glycolylneuraminic acid (Neu5Gc), and 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid (KDN) [1,2]. Although, Sias are widely distributed in higher animals and some microorganisms, only Neu5Ac is ubiquitous, and Neu5Gc is not found in bacteria [2]. Usually, Sias exist in the carbohydrate moiety of glycoconjugates, and are linked to the terminal positions of the carbohydrate chains of the glycoconjugates [2]. The structures of three major sialic acids are described in Figure 1.

Figure 1. Structures of major three sialic acids. (A) *N*-acetylneuraminic acid (Neu5Ac); (B) *N*-glycolylneuraminic acid (Neu5Gc); (C) 2-keto-3-deoxy-D-glycero-D-galacto-noninic acid (KDN).



2.2. Importance of sialyloligosaccharides

In the sialylated glycoconjugates, mainly four linkage patterns, including Neu5Ac α 2-6Gal, Neu5Ac α 2-3Gal, Neu5Ac α 2-6GalNAc, and Neu5Ac α 2-8Neu5Ac, are found [1,2]. These structures are formed by specific sialyltransferases in the cell. As described above, sialyloligosaccharides of glycoconjugates play important roles in many biological processes. For example, the relationship between the structure of carbohydrate chains and the recognition of the host cell by influenza virus is one of the best understood biological phenomena. Many studies have shown that influenza A and B viruses bind to cell surface receptors of host cells via Neu5Ac-linked glycoproteins or glycolipids through viral hemagglutinin recognition of host cell Neu5Ac [14–16]. Furthermore, it has been clearly demonstrated that these influenza viruses also recognize the carbohydrate chain structure of the host cell [15]. For example, the avian influenza viruses recognize Neu5Ac α 2-3Gal β 1-3/4GlcNAc structures, and the human influenza viruses recognize Neu5Ac α 2-6Gal β 1-3/4GlcNAc structures [14,15]. The host cell specificity of the influenza viruses is determined mainly by the linkage of Neu5Ac to the penultimate galactose residues and core structures. Thus, the distribution of Neu5Ac and its linkage patterns on the host cell surface are important determinants of host tropism [17,18].

3. Sialyltransferase

3.1. Classes and sources sialyltransferases

To date, many sialyltransferases have been obtained from mammals, bacteria and viruses [8,19,20]. They are classified into four families according to the carbohydrate linkages they synthesize: the beta-galactoside α 2,3-sialyltransferases (ST3Gal I–VI), the beta-galactoside α 2,6-sialyltransferases (ST6Gal I, II), the GalNAc α 2,6-sialyltransferases (ST6GalNAc I–VI), and the α 2,8-sialyltransferases (ST8Sia I–VI) [8]. On the other hand, all the sialyltransferases have been also classified into five families on the basis of sequence similarities in the CAZy (carbohydrate-active enzymes) database [21], *i.e.*, glycosyltransferase family (GT) 29, various sialyltransferases from eukaryotes and viruses; family 38, polysialyltransferase from bacteria such as *Escherichia coli*; family 42, lipooligosaccharide α 2,3-sialyltransferase from bacteria such as *Campylobacter jejuni*; family 52, α 2,3-sialyltransferase from bacteria such as *Neisseria gonorrhoeae*; and family 80, α 2,6-sialyltransferase from marine bacteria such as *Photobacterium damsela*.

It has been revealed that mammalian sialyltransferases contain conserved sequence motifs, including sialyl motifs L, S, VS and motif III [22–24]. Very recently, a crystal structure of the mammalian sialyltransferase was reported [25]. Some functions of these motifs have been clarified. For example, mutagenesis studies have demonstrated that motif L is involved in donor substrate binding [26] and that motif S is involved in donor and acceptor substrate binding [22]. Like the mammalian sialyltransferases, viral α 2,3-sialyltransferase, obtained from myxoma-virus-infected RK13 cells, contains the motifs L and S in its catalytic domain and is closely related to mammalian α 2,3-sialyltransferase (ST3Gal IV) on the basis of amino acid sequence similarity [20]. The substrate specificity of the viral and mammalian sialyltransferases is very different, despite the common presence of the sialyl motifs.

The known bacterial sialyltransferases do not contain the sialyl motifs found in mammalian sialyltransferases [19,20]. Two short motifs, referred to as the D/E-D/E-G and HP motifs, have been recently identified in the bacterial sialyltransferases and are shown to be functionally important for enzyme catalysis and donor substrate binding [27]. These two motifs are structurally distinct from the motifs found in mammalian sialyltransferases. Furthermore, it has been also demonstrated that the three conserved functional motifs, named YDDGS motif, FKGHP motif and SS motif, exist in the bacterial sialyltransferases that have been classified into GT family 80 [28].

3.2. Classification of sialyltransferases produced by bacteria

Genes encoding sialyltransferases have been cloned from various types of bacteria, including *N. gonorrhoeae* [29], *Neisseria meningitidis* [30], *C. jejuni* [31], *E. coli* [32], *P. damsela* [33], *Photobacterium phosphoreum* [34], *Photobacterium leiognathi* [35,36], *Photobacterium* sp. [37], *Vibrio* sp. [38], *Pasteurella multocida* [39], *Haemophilus influenzae* [40], and *Streptococcus agalactiae* [41]. As described above, all bacterial sialyltransferases are classified into four families in the CAZy database: (1) glycosyltransferase (GT) family 38 (polysialyltransferase from *E. coli* and *N. meningitidis*); (2) GT family 42 (lipooligosaccharide α 2,3-sialyltransferase and α 2,3-/ α 2,8-sialyltransferase from *C. jejuni* and *H. influenzae*); (3) GT family 52 (α 2,3-sialyltransferase from *H. influenzae*, *N. gonorrhoeae*, and *N. meningitidis*); and (4) GT family 80 (α 2,6-sialyltransferase and α 2,3-/ α 2,6-sialyltransferase from *P. damsela* and *P. multocida*). Some marine bacterial sialyltransferases also show both sialyltransferase and neuraminidase activities. The relationship between the marine bacterial sialyltransferases and type of enzyme activities is listed in Table 1.

Table 1. The relationship between marine bacteria and enzyme activities.

Enzyme origin	Enzyme activities	
	Sialyltransferase activity	Neuraminidase activity
<i>Photobacterium phosphoreum</i> JT-ISH-467	α 2,3-sialyltransferase	+
<i>Photobacterium</i> sp. JT-ISH-224		+
<i>Vibrio</i> sp. JT-FAJ-16		–
<i>Photobacterium damsela</i> JT0160	α 2,6-sialyltransferase	–
<i>Photobacterium leiognathi</i> JT-SHIZ-119		+
<i>Photobacterium leiognathi</i> JT-SHIZ-145		–
<i>Photobacterium</i> sp. JT-ISH-224		–


Recently, it has been also reported that marine bacteria producing α 2,6-sialyltransferases express Neu5Ac residue on their cell surfaces [42]. Among the bacteria producing α 2,6-sialyltransferases, *P. damsela* is known as a causative agent of wound infection, ulceration and pasteurellosis [43–45]. As described in the introduction, sialyloligosaccharides are important molecules for cell–cell interaction and infection. Although the structures of the sialyloligosaccharides produced by the bacteria are still unknown, the molecules containing Neu5Ac on their cell surfaces that might be produced by the enzymes may be involved in virulence and adhesion to host cells.

4. Enzymatic Properties of Marine Bacterial Sialyltransferases

4.1. An α 2,6-sialyltransferase produced by *P. damsela* JT0160

To date, it has been demonstrated that the α 2,6-sialyltransferase produced by *P. damsela* JT0160 has unique acceptor substrate specificity compared with the mammalian counterparts. First, it has been revealed that *P. damsela* α 2,6-sialyltransferase transfers Neu5Ac to both glycoproteins including asialo-*N*-linked and asialo-*O*-linked glycoproteins and glycolipids [46,47]. However, rat liver α 2,6-sialyltransferase has a K_m value approximately 33-times higher for lactose than for *N*-acetyllactosaminide, *P. damsela* α 2,6-sialyltransferase recognizes lactose and *N*-acetyllactosaminide as acceptor substrates with almost equal K_m values [48]. These results indicate that *P. damsela* α 2,6-sialyltransferase does not recognize the 2-acetamido group in the *N*-acetylglucosaminyl residue, unlike the mammalian enzymes. The acceptor substrate specificity of mammalian sialyltransferases is generally high, and mammalian enzymes are specific for the type of the sugars and linkages. For example, mammalian sialyltransferases do not recognize fucosylated carbohydrate chains as an acceptor substrate. In eukaryotes, the carbohydrate chain moieties of glycoconjugate are synthesized by a series of glycosyltransferases, and the order of glycosylation is determined strictly. Usually, fucosylation is performed by fucosyltransferases after sialylation in mammalian cell. Thus, mammalian sialyltransferases do not recognize fucosylated carbohydrate chains as acceptor substrates and cannot transfer Neu5Ac to them. However, *P. damsela* α 2,6-sialyltransferase does recognize fucosylated carbohydrate chains as an acceptor substrate and transfers Neu5Ac to the galactose residue of carbohydrate chains at position 6 in 2'-fucosyllactose [49]. In addition, the α 2,6-sialyltransferase also recognizes 3'-sialyllactose and gives 3',6'-disialyllactose as the reaction product [49]. The structures of the reaction products derived from 2'-fucosyllactose and 3'-sialyllactose are described in Figure 2.


Figure 2. Structures of the enzymatic reaction products derived from 2'-fucosyllactose and 3'-sialyllactose. (A) Reaction product derived from 2'-fucosyllactose; (B) Reaction product derived from 3'-sialyllactose.



The *P. damsela* α 2,6-sialyltransferase is less specific, which may allow various sialylated glycans to be prepared, as described above. Furthermore, it has been revealed that the α 2,6-sialyltransferase uses both Gal β 1,3GlcNAc and Gal β 1,6GlcNAc as acceptor substrates and gives the corresponding

enzymatic reaction products, respectively [50]. These results indicate that this $\alpha 2,6$ -sialyltransferase is not sensitive to the nature of the second sugar from the non-reducing terminus and to the linkage between the terminal two sugars. The structures of the reaction products derived from Gal β 1,3GlcNAc and Gal β 1,6GlcNAc are described in Figure 3.

Figure 3. Structures of the enzymatic reaction products derived from Gal β 1,3GlcNAc and Gal β 1,6GlcNAc. (A) Reaction product derived from Gal β 1,3GlcNAc; (B) Reaction product derived from Gal β 1,6GlcNAc.




It has been also revealed that the $\alpha 2,6$ -sialyltransferase has unique donor substrate specificity. The sialyltransferase recognizes CMP-Neu5Ac, CMP-KDN as donor substrates and many CMP-sialic acid derivatives with the non-natural modification of an azido or acetylene group at positions C5, C7, C8, and/or C9 [51,52].

4.2. An $\alpha 2,6$ -sialyltransferase produced by *Photobacterium* sp. JT-ISH-224

Except $\alpha 2,6$ -sialyltransferase produced by *P. damsela* JT0160, three additional genes encoding the marine bacterial $\alpha 2,6$ -sialyltransferase have been cloned from *Photobacterium* sp. JT-ISH-224 [37], *P. leiognathi* JT-SHIZ-145 [35] and *P. leiognathi* JT-SHIZ-119 [36]. These genes have all been expressed as recombinant active form enzymes in an *E. coli* protein expression system. Among them, $\alpha 2,6$ -sialyltransferase cloned from *Photobacterium* sp. JT-ISH-224 has been shown to display the highest specific activity. A homology search shows that the amino acid sequence of the $\alpha 2,6$ -sialyltransferase from JT-ISH-224 has 54% identity to $\alpha 2,6$ -sialyltransferase cloned from *P. damsela* JT0160. The enzymatic property of the $\alpha 2,6$ -sialyltransferase cloned from *Photobacterium* sp. JT-ISH-224 is similar to that of the $\alpha 2,6$ -sialyltransferase cloned from *P. damsela* JT0160. To date, it has been revealed that the $\alpha 2,6$ -sialyltransferase cloned from JT-ISH-224 can transfer Neu5Ac to both O-6 and O-6' hydroxyl groups of lactose simultaneously and gives 6,6'-disialyllactose, and transfers KDO (2-keto-3-deoxyoctonate) to the O-6' hydroxyl group of lactose and gives KDO-lactose [53]. The structures of the reaction products described here are shown in Figure 4.


Figure 4. Structures of enzymatic reaction products produced by the α 2,6-sialyltransferase cloned from JT-ISH-224. (A) 6,6'-sialyllactose; (B) KDO-lactose.



4.3. An α 2,3-sialyltransferase produced by *P. phosphoreum* JT-ISH-467


To date, three genes encoding the marine bacterial α 2,3-sialyltransferase have been cloned from *Photobacterium* sp. JT-ISH-224 [37], *P. phosphoreum* JT-ISH-467 [34] and *Vibrio* sp. JT-FAJ-16 [38] and all these genes have been expressed as recombinant active form enzymes in an *E. coli* protein expression system. During the course of 3'-sialyllactose production using α 2,3-sialyltransferase cloned from *Photobacterium* sp. JT-ISH-224, it has been revealed that the α 2,3-sialyltransferase can transfer Neu5Ac to both O-2 and O-3' hydroxyl groups of lactose simultaneously, giving 2,3'-disialyllactose as an enzymatic reaction product [54]. By NMR spectroscopy analysis, it has been confirmed that the reaction product contain only α -form. The relative configuration between C-1 to C-3 of the α -glucopyranose residue is superimposable with that between C-4 to C-2 of galactopyranose. Therefore, it is expected that the enzyme recognizes the α -glucopyranose residue as acceptor substrate and transfers Neu5Ac to O-2 hydroxyl group of the α -glucopyranose. In addition, it has been also demonstrated that the α 2,3-sialyltransferase can transfer Neu5Ac to the β -anomeric hydroxyl groups of mannose and gives the corresponding reaction product [50]. In this case, the stereochemistry of β -mannose residue from C-2 to O-5 in the pyranose ring is superimposable on that from C-4 to C-2 of galactopyranose, except for the difference between the C-2 carbon atom in the Gal and O-5 oxygen atom in the Man [50]. Thus, it is strongly expected that the α 2,3-sialyltransferase recognizes the acceptor substrate mainly through the stereochemical structure of the C-4 to C-3 of Gal [50]. The structures of the reaction products produced by the enzyme are shown in Figure 5.

Figure 5. Structures of enzymatic reaction products produced by the α 2,3-sialyltransferase cloned from JT-ISH-224. (A) Enzymatic reaction product derived from lactose; (B) Enzymatic reaction product derived from mannose.



Very recently, it has been also reported that this α 2,3-sialyltransferase can catalyze the transfer of Neu5Ac residue to inositols, non-carbohydrates, as well as to carbohydrates with a diol structure corresponding to the C-3 and C-4 of the galactopyranose moiety. As described, the α 2,3-sialyltransferase does recognize both *epi*-inositol and 1_D -*chiro*-inositol as acceptor substrates, and gives the corresponding reaction products [55]. The structures of the reaction products derived from *epi*-inositol and 1_D -*chiro*-inositol are described in Figure 6.

Figure 6. Structures of the enzymatic reaction products derived from *epi*-inositol and 1_D -*chiro*-inositol. (A) Reaction product derived from *epi*-inositol; (B) Reaction product derived from 1_D -*chiro*-inositol.



5. Application of Sialyltransferases

5.1. Production of sialyloligosaccharides

A remarkable oligosaccharide production method has been reported using a single growing metabolically engineered bacterium [56]. In this method, oligosaccharides are produced in a bacterium that overexpresses the recombinant glycosyltransferase genes and that maintains the pool level of the sugar nucleotides by its enzymatic cellular machinery [57,58]. To date, it has been reported that several oligosaccharides, such as lacto-*N*-neotetraose, lacto-*N*-neoheaxose, and sialyllactose, are efficiently produced by this method using bacterial glycosyltransferases, such as β 1,3-*N*-acetylglucosaminyltransferase, β 1,4-galactosyltransferase and α 2,3-sialyltransferase from *N. meningitidis*, α 1,2-fucosyltransferase from *Helicobacter pylori*, etc.[56–58]. Very recently, it has been also reported that more than 25 g/L of both 6'-sialyllactose and 3'-sialyllactose have been

produced by a high-density cell culture of *E. coli* strains overexpressing bacterial sialyltransferases of α 2,6-sialyltransferase from *Photobacterium* sp. and α 2,3-sialyltransferase from *N. meningitidis*, respectively [53,59]. In the case of the sialyllactose production system using the transformed bacterium by *Photobacterium* sp. JT-ISH-224 α 2,6-sialyltransferase gene, formation of KDO-lactose and 6,6'-disialyllactose has been observed as well as 6'-sialyllactose production [53]. On the other hand, no formation of by-product has been observed in case of sialyllactose production system using the transformed bacterium by the *N. meningitidis* α 2,3-sialyltransferase gene. These results indicate that the 6'-sialyllactose production system with marine bacterial sialyltransferase has the possibility to produce various kinds of sialylated carbohydrate chains, but examination of the culture conditions are necessary to efficiently produce the compounds aimed for [53].

5.2. Application of sialyloligosaccharides

As described above, influenza A and B viruses infect host cells through the binding of viral hemagglutinins to sialylglycoproteins or sialylglycolipids of the receptors on the host cell surface [7,14–18]. These influenza viruses recognize both sialic acid in the receptor on the cell surface and carbohydrate chain structures on the cell surface including Neu5Ac α 2-3(6)Gal β 1-3GlcNAc (sialyl-lacto series Type I) or Neu5Ac α 2-3(6)Gal β 1-4GlcNAc (sialyl-lacto series Type II). Therefore, molecules with the carbohydrate chain structures described above are thought to be potential inhibitors of infection by influenza virus or to be materials for influenza virus adsorption [60]. In addition, the ability of influenza viruses to recognize sialyloligosaccharides is known to be enhanced by the clustering of sialyloligosaccharides on macromolecules [61]. Thus, a variety of glycopolymers with multivalent sialyloligosaccharides that target influenza viral hemagglutinins have been synthesized for developing influenza virus inhibitors or adsorption materials [60]. Up to present, various glycopolymers carrying sialyloligosaccharides have been produced using polyacrylamide, γ -polyglutamic acid, polystyrene, chitosan and dendrimers as the polymer backbone, and their inhibition of influenza virus infection has also been demonstrated [60–68].

Recently, it has been clearly demonstrated that sialyllactose (Neu5Ac α 2-3(6)Gal β 1-4Glc), Neu5Ac and *N*-acetylmannosamine could be candidates for prophylactic drugs to distal myopathy with rimmed vacuoles (DMRV)-hereditary inclusion body myopathy (hIBM), which is a moderately progressive autosomal recessive myopathy [69]. The disease gene underlying DMRV-hIBM has been predicted to be GNE, encoding UDP-*N*-acetylglucosamine-2-epimerase and *N*-acetylmannosamine kinase [70,71]. These enzymes are essential for sialic acid biosynthesis. Thus, the patients who have this disease show hyposialylation in various organs [72]. A prophylactic treatment with sialyllactose, Neu5Ac and *N*-acetylmannosamine was tested to confirm effectiveness in a mouse model of DMRV-hIBM. Oral treatment with the sialic acid metabolites described above completely precluded the development of the myopathic phenotype in the model mice [72]. Therefore, it is strongly expected that DMRV-hIBM in humans can potentially be treated by oral addition of sialic acid metabolites, such as sialyllactose, Neu5Ac and *N*-acetylmannosamine, and their derivatives.

Acknowledgements

The author would like to thank all of his colleagues and collaborators.

References

1. Schauer, R. Sialic acid: fascinating sugars in higher animals and man. *Zoology* **2004**, *107*, 49–64.
2. Angata, T.; Varki, A. Chemical diversity in the sialic acids and related α -keto acids: an evolutionary perspective. *Chem. Rev.* **2002**, *102*, 439–469.
3. Paulson, J.C. Glycoproteins: What are the sugar chains for? *Trends Biochem. Sci.* **1989**, *14*, 272–276.
4. Hakomori, S. Bifunctional role of glycosphingolipids. *J. Biol. Chem.* **1990**, *265*, 18713–18716.
5. Lasky, L.A. Selectins: Interpreters of cell-specific carbohydrate information during inflammation. *Science* **1992**, *258*, 964–969.
6. Kannagi, R. Regulatory roles of carbohydrate ligands for selectins in homing of lymphocytes. *Curr. Opin. Struct. Biol.* **2002**, *12*, 599–608.
7. Suzuki, Y. Sialobiology of influenza: molecular mechanism of host range variation of influenza virus. *Biol. Pharm. Bull.* **2005**, *28*, 399–408.
8. Taniguchi, N.; Honke, K.; Fukuda, M. *Handbook of Glycosyltransferases and Related Genes*, 1st ed.; Springer-Verlag: Tokyo, Japan, 2002; pp. 267–356.
9. Schmidt, R.R. New methods for the synthesis of glycosides and oligosaccharides—Are there alternatives to the Koenigs-Knorr method? New Synthetic Methods. *Angew. Chem. Int. Ed. Engl.* **1986**, *25*, 212–235.
10. Kanie, O.; Hindsgaul, O. Synthesis of oligosaccharides, glycolipids and glycopeptides. *Curr. Opin. Struct. Biol.* **1992**, *2*, 674–681.
11. Wang, Z.; Zhang, X.-F.; Ito, Y.; Nakahara, Y.; Ogawa, T. A new strategy for stereoselective synthesis of sialic acid-containing glycopeptide fragment. *Bioorg. Med. Chem.* **1996**, *4*, 1901–1908.
12. Izumi, M.; Wong, C.-H. Microbial sialyltransferases for carbohydrate synthesis. *Trends Glycosci. Glycotechnol.* **2001**, *13*, 345–360.
13. Yamamoto, T.; Takakura, Y.; Tsukamoto, H. Bacterial sialyltransferase. *Trends Glycosci. Glycotechnol.* **2006**, *18*, 253–265.
14. Connor, R.J.; Kawaoka, Y.; Webster, R.G.; Paulson, J.C. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. *Virology* **1994**, *205*, 17–23.
15. Rogers, G.N.; Paulson, J.C. Receptor determinations of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. *Virology* **1983**, *127*, 361–373.
16. Suzuki, Y.; Ito, T.; Suzuki, T.; Holland, R.E., Jr.; Chambers, T.M.; Kiso, M.; Ishida, H.; Kawaoka, Y. Sialic acid species as a determinant of the host range of influenza A virus. *J. Virol.* **2000**, *74*, 11825–11831.
17. Yamada, S.; Suzuki, Y.; Suzuki, T.; Li, M.Q.; Nidom, C.A.; Sakai-Tagawa, Y.; Muramoto, Y.; Ito, M.; Kiso, M.; Hiromoto, T.; *et al.* Hemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. *Nature* **2006**, *444*, 378–382.
18. Suzuki, Y. Gangliosides as influenza virus receptors. Variation of influenza viruses and their recognition of the receptor sialo-sugar chains. *Prog. Lipid Res.* **1994**, *33*, 429–457.
19. Koizumi, S. Large-scale production of oligosaccharides using bacterial functions. *Trends Glycosci. Glycotechnol.* **2003**, *15*, 65–74.

20. Sujino, K.; Jackson, R.J.; Chan, N.W.C.; Tsuji, S.; Palcic, M.M. A novel viral α 2,3-sialyltransferase (v-ST3Gal I): Transfer of sialic acid to fucosylated acceptors. *Glycobiology* **2000**, *10*, 313–320.
21. Coutinho, P.M.; Deleury, E.; Davies, G.J.; Henrissat, B. An evolving hierarchical family classification for glycosyltransferases. *J. Mol. Biol.* **2003**, *328*, 307–317.
22. Datta, A.K.; Sinha, A.; Paulson, J.C. Mutation of the sialyltransferase S-sialylmotif alters the kinetics of the donor and acceptor substrates. *J. Biol. Chem.* **1998**, *273*, 9608–9618.
23. Sasaki, K. Molecular cloning and characterization of sialyltransferase. *Trends Glycosci. Glycotechnol.* **1996**, *8*, 195–215.
24. Jeanneau, C.; Chazalet, V.; Augé, C.; Soumpasis, D.M.; Harduin-Lepers, A.; Delannoy, P.; Imbert, A.; Breton, C. Structure-function analysis of the human sialyltransferase ST3Gal I: role of N-glycosylation and a novel conserved sialylmotif. *J. Biol. Chem.* **2004**, *279*, 13461–13468.
25. Rao, F.V.; Rich, J.R.; Rakić, B.; Buddai, S.; Schwartz, M.F.; Johnson, K.; Bowe, C.; Wakarchuk, W.W.; Defrees, S.; Withers, S.G.; Strynadka, N.C. Structural insight into mammalian sialyltransferases. *Nat. Struct. Mol. Biol.* **2009**, *16*, 1186–1188.
26. Datta, A.K.; Paulson, J.C. The sialyltransferase “Sialylmotif” participates in binding the donor substrate CMP-NeuAc. *J. Biol. Chem.* **1995**, *270*, 1497–1500.
27. Freiburger, F.; Claus, H.; Gunzel, A.; Oltmann-Norden, I.; Vionnet, J.; Muhlenhoff, M.; Vogel, U.; Vann, W.F.; Gerardy-Schahn, R.; Stummeyer, K. Biochemical characterization of a *Neisseria meningitidis* polysialyltransferase reveals novel functional motifs in bacterial sialyltransferases. *Mol. Microbiol.* **2007**, *65*, 1258–1275.
28. Yamamoto, T.; Ichikawa, M.; Takakura, Y. Conserved amino acid sequences in the bacterial sialyltransferases belonging to Glycosyltransferase family 80. *Biochem. Biophys. Res. Commun.* **2008**, *365*, 340–343.
29. Gilbert, M.; Watson, D.C.; Cunningham, A.M.; Jennings, M.P.; Young, N.M.; Wakarchuk, W.W. Cloning of the lipooligosaccharide α -2,3-sialyltransferase from the bacterial pathogens *Neisseria meningitidis* and *Neisseria gonorrhoeae*. *J. Biol. Chem.* **1996**, *271*, 28271–28276.
30. Edwards, U.; Muller, A.; Hammerschmidt, S.; Gerardy-Schahn, R.; Frosch, M. Molecular analysis of the biosynthesis pathway of the (α -2,8) polysialic acid capsule by *Neisseria meningitidis* serogroup B. *Mol. Microbiol.* **1994**, *14*, 141–149.
31. Gilbert, M.; Brisson, J.R.; Karwaski, M.F.; Michniewicz, J.; Cunningham, A.M.; Wu, Y.; Young, N.M.; Wakarchuk, W.W. Biosynthesis of ganglioside mimics in *Campylobacter jejuni* OH4384: Identification of the glycosyltransferase genes, enzymatic synthesis of model compounds, and characterization of nanomole amounts by 600-MHz ^1H and ^{13}C NMR analysis. *J. Biol. Chem.* **2000**, *275*, 3896–3906.
32. Shen, G.J.; Datta, A.K.; Izumi, M.; Koeller, K.M.; Wong, C.-H. Expression of α 2,8/2,9-Polysialyltransferase from *Escherichia coli* K92. characterization of the enzyme and its reaction products. *J. Biol. Chem.* **1999**, *274*, 35139–35146.
33. Yamamoto, T.; Nakashizuka, M.; Terada, I. Cloning and expression of a marine bacterial β -galactoside α 2,6-sialyltransferase gene from *Photobacterium damsela* JT0160. *J. Biochem.* **1998**, *123*, 94–100.

34. Tsukamoto, H.; Takakura, Y.; Yamamoto, T. Purification, cloning and expression of an α - β -galactoside α 2,3-sialyltransferase from a luminous marine bacterium, *Photobacterium phosphoreum*. *J. Biol. Chem.* **2007**, *282*, 29794–29802.
35. Yamamoto, T.; Hamada, Y.; Ichikawa, M.; Kajiwara, H.; Mine, T.; Tsukamoto, H.; Takakura, Y. A β -galactoside α 2,6-sialyltransferase produced by a marine bacterium, *Photobacterium leiognathi* JTSHIZ-145, is active at pH 8. *Glycobiology* **2007**, *17*, 1167–1174.
36. Mine, T.; Katayama, S.; Kajiwara, H.; Tsunashima, M.; Tsukamoto, T.; Takakura, Y.; Yamamoto, T. An α 2,6-sialyltransferase cloned from *Photobacterium leiognathi* strain JT-SHIZ-119 shows both sialyltransferase and neuraminidase activity. *Glycobiology* **2010**, *20*, 158–165.
37. Tsukamoto, H.; Takakura, Y.; Mine, T.; Yamamoto, T. *Photobacterium* sp. JT-ISH-224 Produces Two Sialyltransferases, α - β -Galactoside α 2,3-Sialyltransferase and β -Galactoside α 2,6-Sialyltransferase. *J. Biochem.* **2008**, *143*, 187–197.
38. Takakura, Y.; Tsukamoto, H.; Yamamoto, T. Molecular cloning, expression and properties of an α / β -galactoside α 2,3-sialyltransferase from *Vibrio* sp. JT-FAJ-16. *J. Biochem.* **2007**, *142*, 403–412.
39. Yu, H.; Chokhawala, H.; Karpel, R.; Yu, H.; Wu, B.; Zhang, J.; Zhang, Y.; Jia, Q.; Chen, X. A multifunctional *Pasteurella multocida* sialyltransferase: A powerful tool for the synthesis of sialoside libraries. *J. Am. Chem. Soc.* **2005**, *127*, 17618–17619.
40. Hood, D.W.; Cox, A.D.; Gilbert, M.; Makepeace, K.; Walsh, S.; Deadman, M.E.; Cody, A.; Martin, A.; Mansson, M.; Schweda, E.K.; Brisson, J.R.; Richards, J.C.; Moxon, E.R.; Wakarchuk, W.W. Identification of a lipopolysaccharide α -2,3-sialyltransferase from *Haemophilus influenzae*. *Mol. Microbiol.* **2001**, *39*, 341–350.
41. Watanabe, M.; Miyake, K.; Yamamoto, S.; Kataoka, Y.; Koizumi, S.; Endo, T.; Ozaki, A.; Iijima, S. Identification of sialyltransferases of *Streptococcus agalactiae*. *J. Biosci. Bioeng.* **2002**, *93*, 610–613.
42. Kajiwara, H.; Toda, M.; Mine, T.; Nakada, H.; Wariishi, H.; Yamamoto, T. Visualization of sialic acid produced on bacterial cell surfaces by lectin staining. *Microbes Environ.* **2010**, *25*, 152–155.
43. Austin, B. Vibrios as causal agents of zoonoses. *Vet. Microbiol.* **2010**, *140*, 310–317.
44. Jung, T.S.; Thompson, K.D.; Adams, A. A comparison of sialic acid between different isolates of *Photobacterium damsela* subsp. piscicida. *Fish Pathol.* **2001**, *36*, 217–224.
45. Love, M.; Teebken-Fisher, D.; Mecca, M. The marine bacterium *Vibrio damsela* sp. causes skin ulcers on the damselfish *Chromis punctipinnis*: Association with human infections. *Science* **1981**, *214*, 1139–1140.
46. Yamamoto, T.; Nagae, H.; Kajihara, Y.; Terada, I. Mass production of bacterial α 2,6-sialyltransferase and enzymatic syntheses of sialyloligosaccharides. *Biosci. Biotechnol. Biochem.* **1998**, *62*, 210–214.
47. Kushi, Y.; Kamimiya, H.; Hiratsuka, H.; Nozaki, H.; Fukui, H.; Yanagida, M.; Hashimoto, M.; Nakamura, K.; Watarai, S.; Kasama, T.; Kajiwara, H.; Yamamoto, T. Sialyltransferases of marine bacteria efficiently utilize glycosphingolipid substrates. *Glycobiology* **2010**, *20*, 187–198.
48. Yamamoto, T.; Nakashizuka, M.; Kodama, H.; Kajihara, Y.; Terada, I. Purification and characterization of a marine bacterial β -galactoside α 2,6-sialyltransferase from *Photobacterium damsela* JT0160. *J. Biochem.* **1996**, *120*, 104–110.

49. Kajihara, Y.; Yamamoto, T.; Nagae, H.; Nakashizuka, M.; Sakakibara, T.; Terada, I. A Novel α 2,6-Sialyltransferase: Transfer of Sialic Acid to Fucosyl and Sialyl Trisaccharides. *J. Org. Chem.* **1996**, *61*, 8632–8635.
50. Mine, T.; Miyazaki, T.; Kajiwara, H.; Naito, K.; Ajisaka, K.; Yamamoto, T. Enzymatic synthesis of unique sialyloligosaccharides using marine bacterial α -(2→3)- and α -(2→6)-sialyltransferases. *Carbohydr. Res.* **2010**, *345*, 1417–1421.
51. Kajihara, Y.; Akai, S.; Nakagawa, T.; Sato, R.; Ebata, T.; Kodama, H.; Sato, K. Enzymatic synthesis of Kdn oligosaccharides by a bacterial α -(2→6)-sialyltransferase. *Carbohydr. Res.* **1999**, *315*, 137–141.
52. Yu, H.; Huang, S.; Chokhawala, H.; Sun, M.; Zheng, H.; Chen, X. Highly efficient chemoenzymatic synthesis of naturally occurring and non-natural alpha-2,6-linked sialosides: A *P. damsela* alpha-2,6-sialyltransferase with extremely flexible donor-substrate specificity. *Angew. Chem. Int. Ed. Engl.* **2006**, *45*, 3938–3944.
53. Drouillard, S.; Mine, T.; Kajiwara, H.; Yamamoto, T.; Samain, E. Efficient synthesis of 6'-sialyllactose, 6',6-disialyllactose and 6'-KDO-lactose by metabolically engineered *Escherichia coli* expressing a multifunctional sialyltransferase from the *Photobacterium* sp. JT-ISH-224. *Carbohydr. Res.* **2010**, *345*, 1394–1399.
54. Mine, T.; Kajiwara, H.; Murase, T.; Kajihara, Y.; Yamamoto, T. An α 2,3-sialyltransferase cloned from *Photobacterium* sp. JT-ISH-224 transfers *N*-acetylneuraminic acid to both O-2 and O-3' hydroxyl groups of lactose. *J. Carbohydr. Chem.* **2010**, *29*, 51–60.
55. Mine, T.; Miyazaki, T.; Kajiwara, H.; Tateda, N.; Ajisaka, K.; Yamamoto, T. A recombinant α -(2→3)-sialyltransferase with an extremely broad acceptor substrate specificity from *Photobacterium* sp. JT-ISH-224 can transfer *N*-acetylneuraminic acid to inositols. *Carbohydr. Res.* **2010**, *345*, 2485–2490.
56. Preim, B.; Gilbert, M.; Wakarchuk, W.W.; Heyraud, A.; Samain, E. A new fermentation process allows large scale production of human milk oligosaccharides by metabolically engineered bacteria. *Glycobiology* **2002**, *12*, 235–240.
57. Antoine, T.; Priem, B.; Heyraud, A.; Greffe, L.; Gilbert, M.; Wakarchuk, W.W.; Lam, J.S.; Samain, E. Large-scale *in vivo* synthesis of the carbohydrate moieties of gangliosides GM1 and GM2 by metabolically engineered *Escherichia coli*. *Chembiochem* **2003**, *4*, 406–412.
58. Drouillard, S.; Driguez, H.; Samain, E. Large-scale synthesis of H-antigen oligosaccharides by expressing *Helicobacter pylori* alpha1,2-fucosyltransferase in metabolically engineered *Escherichia coli* cells. *Angew. Chem. Int. Ed. Engl.* **2006**, *45*, 1778–1780.
59. Fierfort, N.; Samain, E. Genetic engineering of *Escherichia coli* for the economical production of sialylated oligosaccharides. *J. Biotechnol.* **2008**, *134*, 261–265.
60. Tsuchida, A.; Kobayashi, K.; Matsubara, N.; Muramatsu, T.; Suzuki, T.; Suzuki, Y. Simple synthesis of sialyllactose-carrying polystyrene and its binding with influenza virus. *Glycoconj. J.* **1998**, *15*, 1047–1054.
61. Sigal, G.B.; Mammen, M.; Dahmann, G.; Whitesides, G.M. Polyacrylamides bearing pendant α -sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: The strong inhibition reflects enhances binding through cooperative polyvalent interactions. *J. Am. Chem. Soc.* **1996**, *118*, 3789–3800.

62. Makimura, Y.; Watanabe, S.; Suzuki, T.; Suzuki, Y.; Ishida, H.; Kiso, M.; Katayama, T.; Kumagai, H.; Yamamoto, K. Chemoenzymatic synthesis and application of a sialoglycopolymer with a chitosan backbone as a potent inhibitor of human influenza virus hemagglutination. *Carbohydr. Res.* **2006**, *341*, 1803–1808.
63. Choi, S.-K.; Mammen, M.; Whitesides, G.M. Generation and *in situ* evaluation of libraries of poly(acrylic acid) presenting sialosides as side chains as polyvalent inhibitors of influenza-mediated hemagglutination. *J. Am. Chem. Soc.* **1997**, *119*, 4103–4111.
64. Umemura, M.; Itoh, M.; Makimura, Y.; Yamazaki, K.; Umekawa, M.; Masui, A.; Matahira, Y.; Shibata, M.; Ashida, H.; Yamamoto, K. Design of a sialylglycopolymer with a chitosan backbone having efficient inhibitory activity against influenza virus infection. *J. Med. Chem.* **2008**, *51*, 4496–4503.
65. Totani, K.; Kubota, T.; Kuroda, T.; Murata, T.; Hidari, K.I.-P.J.; Suzuki, T.; Suzuki, Y.; Kobayashi, K.; Ashida, H.; Yamamoto, K.; Usui, T. Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses. *Glycobiology* **2003**, *13*, 315–326.
66. Furuike, T.; Aiba, S.; Suzuki, T.; Takahashi, T.; Suzuki, Y.; Yamada, K.; Nishimura, S.-I. Synthesis and anti-influenza virus activity of novel glycopolymers having triantennary oligosaccharide branches. *J. Chem. Soc. Perkin Trans. I* **2000**, *1*, 3000–3005.
67. Mammen, M.; Dahmann, G.; Whitesides, G.M. Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. *J. Med. Chem.* **1995**, *38*, 4179–4190.
68. Reuter, J.D.; Myc, A.; Hayes, M.M.; Gan, Z.; Roy, R.; Qin, D.; Yin, R.; Piehler, L.T.; Esfand, R.; Tomalia, D.A.; Baker, J., Jr. Inhibition of viral adhesion and infection by sialic-conjugated dendritic polymers. *Bioconjug. Chem.* **1999**, *10*, 271–278.
69. Ikeuchi, T.; Asaka, T.; Saito, M.; Tanaka, H.; Higuchi, S.; Tanaka, K.; Saida, K.; Uyama, E.; Mizusawa, H.; Fukuhara, N.; Nonaka, I.; Takemori, M.; Tsuji, S. Gene locus autosomal recessive distal myopathy with rimmed vacuoles maps to chromosome 9. *Ann. Neurol.* **1997**, *41*, 432–437.
70. Eisenberg, I.; Avidan, N.; Potikha, T.; Hochner, H.; Chen, M.; Olender, T.; Barash, M.; Shemesh, M.; Sadeh, M.; Grabov-Nardini, G.; *et al.* The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. *Nat. Genet.* **2001**, *29*, 83–87.
71. Nishino, I.; Noguchi, S.; Murayama, K.; Driss, A.; Sugie, K.; Oya, Y.; Nagata, T.; Chida, K.; Takahashi, T.; Takusa, Y.; *et al.* Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. *Neurology* **2002**, *59*, 1689–1693.
72. Malicdan, M.C.V.; Noguchi, S.; Hayashi, Y.K.; Nonaka, I.; Nishino, I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. *Nat. Med.* **2009**, *15*, 690–695.